# First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

> **NCT06730373** · PHASE2 · RECRUITING · sponsor: **Qilu Hospital of Shandong University** · enrollment: 110 (estimated)

## Conditions studied

- HER2-positive Gastric Cancer
- Metastatic Gastric Cancer
- Unresectable Gastric Carcinoma

## Interventions

- **DRUG:** Disitamab Vedotin
- **DRUG:** Sintilimab
- **DRUG:** S-1
- **DRUG:** Trastuzumab
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** 5-FU
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT06730373
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-17
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2024-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06730373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06730373, "First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06730373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*